188 related articles for article (PubMed ID: 24293056)
21. The effects of desvenlafaxine and paroxetine on the pharmacokinetics of the cytochrome P450 2D6 substrate desipramine in healthy adults.
Nichols AI; Fatato P; Shenouda M; Paul J; Isler JA; Pedersen RD; Jiang Q; Ahmed S; Patroneva A
J Clin Pharmacol; 2009 Feb; 49(2):219-28. PubMed ID: 19001559
[TBL] [Abstract][Full Text] [Related]
22. Exposure to oral oxycodone is increased by concomitant inhibition of CYP2D6 and 3A4 pathways, but not by inhibition of CYP2D6 alone.
Grönlund J; Saari TI; Hagelberg NM; Neuvonen PJ; Olkkola KT; Laine K
Br J Clin Pharmacol; 2010 Jul; 70(1):78-87. PubMed ID: 20642550
[TBL] [Abstract][Full Text] [Related]
23. Effects of CYP2D6 Genetic Polymorphism and Drug Interaction on the Metabolism of Dacomitinib.
Han M; Zhang X; Ye Z; Wang J; Kong Q; Hu X; Qian J; Cai J; Hu G
Chem Res Toxicol; 2022 Feb; 35(2):265-274. PubMed ID: 34936353
[TBL] [Abstract][Full Text] [Related]
24. Effect of low-dose ritonavir (100 mg twice daily) on the activity of cytochrome P450 2D6 in healthy volunteers.
Aarnoutse RE; Kleinnijenhuis J; Koopmans PP; Touw DJ; Wieling J; Hekster YA; Burger DM
Clin Pharmacol Ther; 2005 Dec; 78(6):664-74. PubMed ID: 16338282
[TBL] [Abstract][Full Text] [Related]
25. Physiologically Based Pharmacokinetic Modeling Suggests Limited Drug-Drug Interaction for Fesoterodine When Coadministered With Mirabegron.
Lin J; Goosen TC; Tse S; Yamagami H; Malhotra B
J Clin Pharmacol; 2019 Nov; 59(11):1505-1518. PubMed ID: 31090092
[TBL] [Abstract][Full Text] [Related]
26. Contribution of cytochrome P450 2D6 to 3,4-methylenedioxymethamphetamine disposition in humans: use of paroxetine as a metabolic inhibitor probe.
Segura M; Farré M; Pichini S; Peiró AM; Roset PN; Ramírez A; Ortuño J; Pacifici R; Zuccaro P; Segura J; de la Torre R
Clin Pharmacokinet; 2005; 44(6):649-60. PubMed ID: 15910012
[TBL] [Abstract][Full Text] [Related]
27. Pharmacokinetic interaction of flecainide and paroxetine in relation to the CYP2D6*10 allele in healthy Korean subjects.
Lim KS; Cho JY; Jang IJ; Kim BH; Kim J; Jeon JY; Tae YM; Yi S; Eum S; Shin SG; Yu KS
Br J Clin Pharmacol; 2008 Nov; 66(5):660-6. PubMed ID: 18754843
[TBL] [Abstract][Full Text] [Related]
28. Effects of three cytochrome P450 inhibitors, ketoconazole, fluconazole, and paroxetine, on the pharmacokinetics of lasofoxifene.
Ouellet D; Bramson C; Roman D; Remmers AE; Randinitis E; Milton A; Gardner M
Br J Clin Pharmacol; 2007 Jan; 63(1):59-66. PubMed ID: 16822276
[TBL] [Abstract][Full Text] [Related]
29. Effect of inhibition of cytochrome P450 enzymes 2D6 and 3A4 on the pharmacokinetics of intravenous oxycodone: a randomized, three-phase, crossover, placebo-controlled study.
Grönlund J; Saari TI; Hagelberg NM; Neuvonen PJ; Laine K; Olkkola KT
Clin Drug Investig; 2011; 31(3):143-53. PubMed ID: 21142269
[TBL] [Abstract][Full Text] [Related]
30. The Effect of Hepatic Impairment on the Pharmacokinetics of Dacomitinib.
Piscitelli J; Chen J; LaBadie RR; Salageanu J; Chung CH; Tan W
Clin Drug Investig; 2022 Mar; 42(3):221-235. PubMed ID: 35195881
[TBL] [Abstract][Full Text] [Related]
31. Effects of strong CYP2D6 and 3A4 inhibitors, paroxetine and ketoconazole, on the pharmacokinetics and cardiovascular safety of tamsulosin.
Troost J; Tatami S; Tsuda Y; Mattheus M; Mehlburger L; Wein M; Michel MC
Br J Clin Pharmacol; 2011 Aug; 72(2):247-56. PubMed ID: 21496064
[TBL] [Abstract][Full Text] [Related]
32. Metoprolol-pridopidine drug-drug interaction and food effect assessments of pridopidine, a new drug for treatment of Huntington's disease.
Rabinovich-Guilatt L; Steiner L; Hallak H; Pastino G; Muglia P; Spiegelstein O
Br J Clin Pharmacol; 2017 Oct; 83(10):2214-2224. PubMed ID: 28449367
[TBL] [Abstract][Full Text] [Related]
33. Pharmacokinetic model incorporating mechanism-based inactivation of CYP2D6 can explain both non-linear kinetics and drug interactions of paroxetine.
Mikami A; Ohtani H; Hori S; Sawada Y
Int J Clin Pharmacol Ther; 2013 May; 51(5):374-82. PubMed ID: 23357843
[TBL] [Abstract][Full Text] [Related]
34. Terbinafine increases the plasma concentration of paroxetine after a single oral administration of paroxetine in healthy subjects.
Yasui-Furukori N; Saito M; Inoue Y; Niioka T; Sato Y; Tsuchimine S; Kaneko S
Eur J Clin Pharmacol; 2007 Jan; 63(1):51-6. PubMed ID: 17124578
[TBL] [Abstract][Full Text] [Related]
35. Evaluation of the likelihood of a selective CHK1 inhibitor (LY2603618) to inhibit CYP2D6 with desipramine as a probe substrate in cancer patients.
Hynes SM; Wickremsinhe E; Zhang W; Decker R; Ott J; Chandler J; Mitchell M
Biopharm Drug Dispos; 2015 Jan; 36(1):49-63. PubMed ID: 25296725
[TBL] [Abstract][Full Text] [Related]
36. Effects of paroxetine on the pharmacokinetics and pharmacodynamics of immediate-release and extended-release metoprolol.
Parker RB; Soberman JE
Pharmacotherapy; 2011 Jul; 31(7):630-41. PubMed ID: 21923449
[TBL] [Abstract][Full Text] [Related]
37. Impact of CYP2D6 Functional Allelic Variations on Phenoconversion and Drug-Drug Interactions.
Storelli F; Matthey A; Lenglet S; Thomas A; Desmeules J; Daali Y
Clin Pharmacol Ther; 2018 Jul; 104(1):148-157. PubMed ID: 28940476
[TBL] [Abstract][Full Text] [Related]
38. Effect of the novel anxiolytic drug deramciclane on cytochrome P(450) 2D6 activity as measured by desipramine pharmacokinetics.
Laine K; De Bruyn S; Björklund H; Rouru J; Hänninen J; Scheinin H; Anttila M
Eur J Clin Pharmacol; 2004 Feb; 59(12):893-8. PubMed ID: 14730412
[TBL] [Abstract][Full Text] [Related]
39. Ziprasidone and the activity of cytochrome P450 2D6 in healthy extensive metabolizers.
Wilner KD; Demattos SB; Anziano RJ; Apseloff G; Gerber N
Br J Clin Pharmacol; 2000; 49 Suppl 1(Suppl 1):43S-47S. PubMed ID: 10771453
[TBL] [Abstract][Full Text] [Related]
40. The effects of paroxetine on the pharmacokinetics of paliperidone extended-release tablets.
Berwaerts J; Cleton A; Herben V; van de Vliet I; Chang I; van Hoek P; Eerdekens M
Pharmacopsychiatry; 2009 Jul; 42(4):158-63. PubMed ID: 19585395
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]